DONNA KELLY: Open Payments
NPI 1730566647 · LAUGHLIN, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$771 in 34 payments from 10 companies in 2025. Trend: 2023 $419 · 2024 $596 · 2025 $771
Food & beverage: $771
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 12 | $343 |
| Verona Pharma, Inc. | 5 | $106 |
| Dexcom, Inc. | 3 | $65 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $65 |
| Lilly USA, LLC | 3 | $47 |
| Amgen Inc. | 2 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| ABBVIE INC. | 1 | $27 |
| Exact Sciences Corporation | 1 | $23 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
Products named: Rybelsus, Ozempic, Ohtuvayre, Dexcom G6 Transmitter, Kerendia, OTEZLA, JARDIANCE, GVOKE HYPOPEN.
Industry payments across NV — which companies pay providers there.
